The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer

Figures & data

Table 1 Patient Cohort (IQR=Interquartile Range)

		n (%)
Total cohort		80 (100%)
Gender	Male	61 (76.3)
	Female	19 (23.7)
Median age years (IQR)	71 (46–97)
Median follow-up months (IQR)	62.0 (0.0–189.0)
Tumor grade (WHO 2016)	Low grade	2 (2.5)
	High grade	78 (97.5)
Tumor grade (WHO 1973)	G2	32 (40.0)
	G3	48 (60.0)
Lymphovascular invasion	Yes	2 (2.5)
	No/NA	78 (97.5)
Concomitant CIS	Yes	28 (35.0)
	No/NA	52 (65.0)
Adjuvant instillation	Yes	41 (51.2)
	No	39 (48.8)
Median follow-up months (IQR)	62.0 (0.0–189.0)
Recurrence-free survival (RFS)	Recurrence	41 (51.2)
	No recurrence	39 (48.8)
Progression-free survival (PFS)	Progression	6 (7.5)
	No progression	74 (92.5)
Cancer-specific survival (CSS)	Cancer-specific death	16 (20.0)
	Others	64 (80.0)
Overall survival (OS)	Death	36 (45.0)
	Alive	44 (55.0)

Abbreviations: IQR, interquartile range; CIS, carcinoma in situ; WHO, World Health Organization; NA, not available.

Table 2 Results of Kaplan–Meier Analysis (Log Rank Test): Cut-off Values for FGFR3 and CDKN2A with Regard to Recurrence-Free (RFS), Progression-Free (PFS), Cancer-Specific (CSS) and Overall Survival (OS) for the Total Cohort (n=80)

Marker	Survival	Cut-off Value (40-ΔCt)	n High (%)	n Low (%)	p-value
FGFR3	RFS	42.1	12 (15.0)	68 (85.0)	<0.001
	PFS	38.7	26 (32.5)	54 (67.5)	0.038
	CSS	39.6	35 (43.8)	45 (56.2)	0.067
	OS	39.8	37 (46.2)	43 (53.8)	0.039
CDKN2A	RFS	30.8	12 (15.0)	68 (85.0)	0.285
	PFS	35.6	58 (72.5)	22 (27.5)	0.180
	CSS	35.8	61 (76.2)	19 (23.8)	0.057
	OS	33.4	32 (40.0)	48 (60.0)	0.029

Note: Significant values are in bold.

Table 3 Univariable Cox Regression Analysis for Stratification by Clinicopathological or Molecular Parameters: The Association of FGFR3 and CDKN2A mRNA with OS and RFS

Parameter by Stratification	Overall Survival			Recurrence-Free Survival
	N	HR	p	N	HR	p
Age ≤ 71 years
FGFR3 high vs low	21 vs 19	0.22	0.013	4 vs 36	4.87	0.008
CDKN2A high vs low	22 vs 18	2.94	0.098	33 vs 7	3.88	0.189
Age > 71 years
FGFR3 high vs low	22 vs 18	1.13	0.790	8 vs 32	3.08	0.015
CDKN2A high vs low	26 vs 14	1.50	0.436	35 vs 5	1.01	0.988
KRT5 high
FGFR3 high vs low	25 vs 15	0.27	0.032	9 vs 31	4.92	<0.001
CDKN2A high vs low	21 vs 19	9.06	0.005	32 vs 8	1.71	0.388
KRT5 low
FGFR3 high vs low	18 vs 22	0.80	0.630	3 vs 37	2.78	0.183
FCDKN2A high vs low	27 vs 13	0.76	0.580	36 vs 4	1.95	0.518
KRT20 high
FGFR3 high vs low	26 vs 14	0.43	0.071	10 vs 30	3.43	0.007
CDKN2A high vs low	23 vs 17	3.03	0.049	36 vs 4	1.48	0.596
KRT20 low
FGFR3 high vs low	17 vs 23	0.52	0.226	2 vs 38	2.90	0.160
CDKN2A high vs low	25 vs 15	1.77	0.324	32 vs 8	1.90	0.391
MKI67 high
FGFR3 high vs low	25 vs 15	0.43	0.058	8 vs 32	2.99	0.014
CDKN2A high vs low	24 vs 16	2.13	0.141	35 vs 5	2.06	0.330
MKI67 low
FGFR3 high vs low	18 vs 22	0.40	0.129	4 vs 36	4.59	0.022
CDKN2A high vs low	24 vs 16	2.46	0.164	33 vs 7	1.34	0.700
Instillation
FGFR3 high vs low	21 vs 20	0.35	0.061	6 vs 35	2.61	0.047
CDKN2A high vs low	22 vs 19	2.67	0.092	35 vs 6	1.62	0.434
No instillation
FGFR3 high vs low	22 vs 17	0.81	0.623	6 vs 33	5.44	0.003
CDKN2A high vs low	26 vs 13	1.93	0.241	33 vs 6	2.18	0.454

Note: Significant values are in bold.

Abbreviation: HR, hazard ratio.

Figure 1 Kaplan-Meier analysis of FGFR3 mRNA expression regarding RFS in patients ≤71 years (A) and patients >71 years (B) as well as regarding OS in patients ≤71 years (C) and patients >71 years (D).

Figure 2 Kaplan-Meier analysis of FGFR3 mRNA expression regarding RFS in patients who received no postoperative instillation (A) and patients with postoperative instillation (B).